Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2013, Article ID 541783, 6 pages
http://dx.doi.org/10.1155/2013/541783
Case Report

Cutaneous Plasmablastic Lymphoma in an Immunocompetent Patient with Long-Term Pyrimethamine Use for Essential Thrombocythemia: A Case Report and Literature Review

1Southern Blood and Cancer Service, Dunedin Hospital, Private Bag 1921, Dunedin 9054, New Zealand
2Division of Haematology, Southern Community Laboratories, Dunedin 9016, New Zealand

Received 4 December 2012; Accepted 10 January 2013

Academic Editors: E. Bissé, K. Khair, S. Langabeer, Y. Matsukawa, A. Ohsaka, Y. Shiozawa, and T. Sonoki

Copyright © 2013 Ing Soo Tiong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: International Agency for Research on Cancer, 2008.
  2. H. J. Delecluse, I. Anagnostopoulos, F. Dallenbach et al., “Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection,” Blood, vol. 89, no. 4, pp. 1413–1420, 1997. View at Google Scholar · View at Scopus
  3. J. J. Liu, L. Zhang, E. Ayala et al., “Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review,” Leukemia Research, vol. 35, no. 12, pp. 1571–1577, 2011. View at Publisher · View at Google Scholar
  4. J. J. Castillo, E. S. Winer, D. Stachurski et al., “HIV-negative plasmablastic lymphoma: not in the mouth,” Clinical Lymphoma Myeloma and Leukemia, vol. 11, no. 2, pp. 185–189, 2011. View at Publisher · View at Google Scholar
  5. J. J. Castillo and J. L. Reagan, “Plasmablastic lymphoma: a systematic review,” The Scientific World Journal, vol. 11, pp. 687–696, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. L. Black, E. Foster-Smith, I. D. Lewis et al., “Post-transplant plasmablastic lymphoma of the skin,” Australasian Journal of Dermatology, 2012. View at Publisher · View at Google Scholar
  7. R. Maria, A. Manuel, M. Luisa et al., “Extensive cutaneous involvement by plasmablastic lymphoma,” Journal of the American Academy of Dermatology, vol. 66, no. 4, supplement 1, p. AB137, 2012. View at Publisher · View at Google Scholar
  8. M. Bibas, S. Grisetti, L. Alba, G. Picchi, F. Del Nonno, and A. Antinori, “Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone,” Journal of Clinical Oncology, vol. 28, no. 34, pp. e704–e708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Corti, L. D. Carolis, R. Solari et al., “Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature,” Brazilian Journal of Infectious Diseases, vol. 14, no. 1, pp. 81–85, 2010. View at Google Scholar · View at Scopus
  10. D. Hansra, N. Montague, A. Stefanovic et al., “Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics,” American Journal of Clinical Pathology, vol. 134, no. 5, pp. 710–719, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Apichai, A. Rogalska, I. Tzvetanov, Z. Asma, E. Benedetti, and S. Gaitonde, “Multifocal cutaneous and systemic plasmablastic lymphoma in an infant with combined living donor small bowel and liver transplant,” Pediatric Transplantation, vol. 13, no. 5, pp. 628–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Chabay, E. De Matteo, M. Lorenzetti et al., “Vulvar plasmablastic lymphoma in a HIV-positive child: a novel extraoral localisation,” Journal of Clinical Pathology, vol. 62, no. 7, pp. 644–646, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Hernandez, A. S. Cetner, and E. L. Wiley, “Cutaneous presentation of plasmablastic post-transplant lymphoproliferative disorder in a 14-month-old,” Pediatric Dermatology, vol. 26, no. 6, pp. 713–716, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Jambusaria, D. Shafer, H. Wu, T. Al-Saleem, and C. Perlis, “Cutaneous plasmablastic lymphoma,” Journal of the American Academy of Dermatology, vol. 58, no. 4, pp. 676–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Bernabeu-Wittel, D. H. Gonzalo, R. Luque, J. J. Borrero, and J. Conejo-Mir, “Cutaneous nodules as diagnostic key of an extraoral plasmablastic lymphoma in an human immunodeficiency virus-infected patient,” Journal of the European Academy of Dermatology and Venereology, vol. 22, no. 1, pp. 127–129, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Zaragoza, L. Martínez, A. Pérez-Ferriols, and V. Alegre, “Cutaneous presentation of plasmablastic lymphoma in a patient with HIV Infection,” Actas Dermo-Sifiliográficas, vol. 99, no. 10, pp. 820–821, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Redmond, J. Quinn, P. Murphy, S. Patchett, and M. Leader, “Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn's disease after immunosuppressive therapy,” Journal of Clinical Pathology, vol. 60, no. 1, pp. 80–81, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Arbiser, K. P. Mann, E. M. Losken et al., “Presence of p16 hypermethylation and Epstein-Barr virus infection in transplant-associated hematolymphoid neoplasm of the skin,” Journal of the American Academy of Dermatology, vol. 55, no. 5, pp. 794–798, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Liu, M. E. Lacouture, J. Jiang et al., “KSHV/HHV8-associated primary cutaneous plasmablastic lymphoma in a patient with Castleman's disease and Kaposi's sarcoma,” Journal of Cutaneous Pathology, vol. 33, supplement 2, pp. 46–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. P. Dales, A. Harket, D. Bagnères et al., “Plasmablastic lymphoma in a patient with HIV infection: an unusual case located in the skin,” Annales de Pathologie, vol. 25, no. 1, pp. 45–49, 2005. View at Google Scholar · View at Scopus
  21. S. T. P. Deloose, L. A. Smit, F. T. Pals, M. J. Kersten, C. J. M. Noesel, and S. T. Pals, “High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma,” Leukemia, vol. 19, no. 5, pp. 851–855, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Gilaberte, F. Gallardo, B. Bellosillo et al., “Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma,” British Journal of Dermatology, vol. 153, no. 4, pp. 828–832, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. L. B. Jordan, A. M. Lessells, and J. R. Goodlad, “Plasmablastic lymphoma arising at a cutaneous site,” Histopathology, vol. 46, no. 1, pp. 113–115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Verma, G. E. Frambach, K. H. Seilstad, G. Nuovo, P. Porcu, and C. M. Magro, “Epstein-Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin,” Journal of Cutaneous Pathology, vol. 32, no. 7, pp. 474–483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Verma, G. J. Nuovo, P. Porcu, R. A. Baiocchi, A. N. Crowson, and C. M. Magro, “Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation,” Journal of Cutaneous Pathology, vol. 32, no. 1, pp. 35–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Colomo, F. Loong, S. Rives et al., “Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities,” American Journal of Surgical Pathology, vol. 28, no. 6, pp. 736–747, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. M. Hanasono, B. M. Parrett, and A. S. Breitbart, “Posttransplant lymphoproliferative disorder presenting as a cutaneous forehead mass,” Otolaryngology, vol. 130, no. 3, pp. 372–374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Häusermann, N. Khanna, M. Buess et al., “Cutaneous plasmablastic lymphoma in an HIV-positive male: an unrecognized cutaneous manifestation,” Dermatology, vol. 208, no. 3, pp. 287–290, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. N. J. Samolitis, J. S. Bharadwaj, J. R. Weis, and R. M. Harris, “Post-transplant lymphoproliferative disorder limited to the skin,” Journal of Cutaneous Pathology, vol. 31, no. 6, pp. 453–457, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Teruya-Feldstein, E. Chiao, D. A. Filippa et al., “CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients,” Annals of Oncology, vol. 15, no. 11, pp. 1673–1679, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Nicol, T. Boye, F. Carsuzaa et al., “Post-transplant plasmablastic lymphoma of the skin,” British Journal of Dermatology, vol. 149, no. 4, pp. 889–891, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Liu, N. Asano, A. Tatematsu et al., “Plasmablastic lymphoma of the elderly: a clinicopathological comparison with age-related Epstein-Barr virus-associated B cell lymphoproliferative disorder,” Histopathology, vol. 61, no. 6, pp. 1183–1197, 2012. View at Publisher · View at Google Scholar
  33. A. Jafarzadeh, Z. M. Hassan, M. Ebtekar, S. Mohaghegh-Hazrati, and T. Tiraihi, “Time-dependent changes of immunologic responses after burn injury and immunomodulation by cimetidine and pyrimethamine in an animal model,” Pakistan Journal of Pharmaceutical Sciences, vol. 23, no. 4, pp. 367–373, 2010. View at Google Scholar · View at Scopus
  34. M. Ebtekar and Z. M. Hassan, “Effect of immunomodulators pyrimethamine and cimetidine on immunosuppression induced by sulfur mustard in mice,” International Journal of Immunopharmacology, vol. 15, no. 4, pp. 533–541, 1993. View at Google Scholar · View at Scopus
  35. A. Takakura, E. A. Nelson, N. Haque et al., “Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways,” Human Molecular Genetics, vol. 20, no. 21, pp. 4143–4154, 2011. View at Publisher · View at Google Scholar
  36. A. M. Giammarioli, A. Maselli, A. Casagrande et al., “Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism,” Cancer Research, vol. 68, no. 13, pp. 5291–5300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. R. Khorramizadeh, F. Saadat, F. Vaezzadeh et al., “Suppression of telomerase activity by pyrimethamine: implication to cancer,” Iranian Biomedical Journal, vol. 11, no. 4, pp. 223–228, 2007. View at Google Scholar · View at Scopus
  38. F. Saadat, M. R. Khorramizadeh, and A. Mirshafiey, “Chemoprevention by pyrimethamine,” Immunopharmacology and Immunotoxicology, vol. 27, no. 2, pp. 233–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. S. J. Bowcock, D. C. Linch, S. J. Machin, and J. W. Stewart, “Pyrimethamine in the myeloproliferative disorders: a forgotten treatment?” Clinical and Laboratory Haematology, vol. 9, no. 2, pp. 129–136, 1987. View at Google Scholar · View at Scopus
  40. J. M. Costello and D. M. Becroft, “Drug reaction simulating malignant lymphoma: a case due to pyrimethamine,” New Zealand Medical Journal, vol. 86, no. 599, pp. 430–432, 1977. View at Google Scholar · View at Scopus
  41. F. Passamonti, E. Rumi, E. Pungolino et al., “Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia,” American Journal of Medicine, vol. 117, no. 10, pp. 755–761, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Cortelazzo, G. Finazzi, M. Ruggeri et al., “Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis,” The New England Journal of Medicine, vol. 332, no. 17, pp. 1132–1136, 1995. View at Publisher · View at Google Scholar · View at Scopus
  43. C. N. Harrison, P. J. Campbell, G. Buck et al., “Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia,” The New England Journal of Medicine, vol. 353, no. 1, pp. 33–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. M. H. Steinberg, W. F. McCarthy, O. Castro et al., “The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up,” American Journal of Hematology, vol. 85, no. 6, pp. 403–408, 2010. View at Publisher · View at Google Scholar · View at Scopus